NCT05431426View on ClinicalTrials.gov

PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

CH6001

CHF6001 will be administered using the NEXThaler® DPI device

Trial Locations (1)

1612

MC Comac Medical Ltd., Sofia

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY